Ensign Class Action Lawsuit Allegations
The Ensign class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Ensign securities. The class action is pending in the U.S. District Court for the Central District of California. It is captioned Perusek v. The Ensign Group, Inc., et al., No. 8:26-cv-02963.
If you lost money on your Ensign investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Ensign being Sued for Securities Fraud?
Ensign has been sued for securities fraud following significant stock drops resulting from alleged violations of the federal securities laws. The decline in Ensign’s stock price caused significant losses to investors.
Ensign is a healthcare services company that operates skilled nursing, senior living, and rehabilitative care facilities through affiliated providers. The company relies heavily on Medicare and Medicaid reimbursements, making patient care, staffing, billing, and regulatory compliance central to its business model.
According to the complaint, throughout the Class Period Ensign represented that quality patient care was central to its business, described its clinical outcomes and CMS ratings, and characterized regulatory and compliance risks as contingencies.
The complaint alleges that Ensign concealed systematic understaffing and patient neglect. It also alleges that residents received inadequate food, medical care, and basic supplies. According to the complaint, Ensign manipulated reported quality and staffing data and engaged in improper Medicare and Medicaid billing and upcoding. The complaint further alleges that Ensign used licensed administrators who did not actually manage certain facilities.
Why did Ensign’s Stock Drop?
On June 8, 2026, Hunterbrook Media published “Ensign: The Nursing Home Empire Built on Fatal Neglect,” based on a five-month investigation. The report alleged that Ensign acquired distressed nursing facilities, reduced registered-nurse and other skilled-care hours, used self-reported data to improve quality ratings, and generated profits by providing less care than residents required despite receiving public funds based on patient acuity.
On this news, the price of Ensign stock fell $13.88 per share, or 8.15%, from a closing price of $170.30 per share on June 5, 2026, to $156.42 per share on June 8, 2026.
On June 11, 2026, Muddy Waters Research published “Ensign: Deceiving the Government at Estimated ~20% of Facilities.” The report alleged that Ensign used licensed administrators who were seldom present and did not actually manage certain facilities, while unlicensed operators handled day-to-day operations. Muddy Waters estimated that the alleged practices existed at approximately 20% of Ensign’s skilled nursing facilities and could expose Ensign to significant sanctions, slower growth, and reduced margins.
On this news, the price of Ensign stock fell $4.52 per share, or 2.98%, from a closing price of $151.65 per share on June 10, 2026, to $147.13 per share on June 11, 2026.
On June 18, 2026, Hunterbrook published a follow-up report, “New: Patients Hungry in Ensign Facilities,” alleging additional firsthand evidence of resident hunger, inadequate food and supplies, payroll and staffing-data falsification, understaffing, and employees working above their license levels.
On this news, the price of Ensign stock fell $2.19 per share, or 1.4%, to close at $153.65 per share on June 18, 2026.
The Ensign Group, Inc. (ENSG) Stock Chart
Image Caption: NASDAQ online chart showing Ensign’s (ENSG) stock drop following the June 2026 news.
What is the Ensign Lead Plaintiff Deadline?
You may ask the Court no later than December 7, 2026, to appoint you as Lead Plaintiff through counsel of your choice.
To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
How Do I Submit My Information?
If you lost money when Ensign securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
adam@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of the class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “SuperLawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
